Use of 5% Pueraria mirifica vaginal gel in women with genitourinary syndrome of menopause effectively reduces indicators of bacterial vaginosis but does little to alleviate genitourinary symptoms, according to the results of a trial.
The risk of preterm delivery among pregnant women appears to be elevated in the presence of traditional cardiovascular disease (CVD) risk factors, such as hypertension, diabetes, and increased levels of total cholesterol and low-density lipoprotein (LDL) cholesterol, a study has found.
Sleep disturbance is prevalent during and after menopause, with women with anxiety and depression being at higher risk, a study suggests. Poor sleep status in the premenopausal period predicts is a strong predictor of insomnia at menopausal transition and post-menopause.
Sedentary behaviour remains extremely prevalent among overweight or obese women with polycystic ovary syndrome (PCOS), with a recent study reporting that only one in two women meets physical activity (PA) levels recommended for weight loss.
Local oestrogen preparations may safely and effectively reduce the number of recurrent urinary tract infections (rUTIs) in with genitourinary syndrome of menopause (GSM), delivering symptomatic relief and hence improving quality of life, according to a review.
Gabapentin confers favourable effects in relieving vasomotor symptoms but is less effective than those of oestrogen, results of a systematic review and meta-analysis have shown. In contrast, the therapeutic effects of pregabalin remains unclear.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.